Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P338: Rate and predictors of mucosal healing in patients with ulcerative colitis treated with thiopurines: results of a multicentric cohort studyECCO '16 Amsterdam
Year: 2016
Authors:

C. Prieux-Klotz*1, S. Nahon2, A. Amiot3, L. Sinayoko4, C. Galéano-Cassaz5, S. Chaussade1, P. Lahmek6, V. Abitbol1

1C.H.U. Cochin, Paris, France, 2C.H. Le Raincy Montfermeil, Montfermeil, France, 3C.H.U. Henri Mondor, Créteil, France, 4H.I.A. Bégin, Saint Mandé, France, 5H.I.A. Val de Grâce, Paris, France, 6C.H. Emile Roux, Limeil-Brévannes, France

P339: The efficacy of intravenous iron therapy in IBD patients with active disease is not influenced by the degree of inflammatory activityECCO '16 Amsterdam
Year: 2016
Authors:

A. Walper*1, A. Dignass2, 3, J. Stein3, 4

1Medice Arzneimittel GmbH, Iserlohn, Germany, 2Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany, 3Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 4DGD Clinics Sachsenhausen, Frankfurt/Main, Germany

P340: Postoperative clinical recurrence in Crohn’s disease patients: the Practicrohn studyECCO '16 Amsterdam
Year: 2016
Authors:

E. Domènech*1, V. García2, M. D. Martín Arranz3, M. Barreiro-de Acosta4, A. Gutiérrez5, L. Cea-Calvo6, C. Romero6, B. Juliá6

1Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 2Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain, 3Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, 4Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 5Hospital General Universitario Alicante, Gastroenterology Unit, Alicante, Spain, 6MSD Spain, Medical Department, Madrid, Spain

P341: Analytical performance of a new iPhone-based patient monitoring system comparable to ELISA for measuring faecal calprotectin in inflammatory bowel disease patientsECCO '16 Amsterdam
Year: 2016
Authors:

K. F. Wintgens*1, A. A. Wulandari2, A. Dignass3, 4, F. Hartmann3, 4, J. Stein2, 3

1Immundiagnostik AG, Bensheim, Germany, 2DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 3Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 4Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany

P342: Tryptophan as a biomarker for the course of IBD and anti-TNF α responseECCO '16 Amsterdam
Year: 2016
Authors:

B. Brandt*1, S. Nikolaus2, N. Al-Massad2, J. Bethge2, D. Schuldt2, S. Szymczak3, F. Thieme4, G. H. Waetzig5, M. Krawczak3, R. Junker4, P. Rosenstiel6, S. Schreiber2

1UKSH Kiel, Department of Internal Medicine I, Kiel, Germany, 2UKSH, Department of Internal Medicine I, Kiel, Germany, 3UKSH, Institute of Medical Informatics and Statistics, Kiel, Germany, 4UKSH, Institute of Clinical Chemistry, Kiel, Germany, 5Conaris Research Institute AG, Kiel, Germany, 6UKSH, Institute of Clinical Molecular Biology, Kiel, Germany

P343: The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease and the relationship with biochemical markers of disease activityECCO '16 Amsterdam
Year: 2016
Authors:

K. Diederen1, D. Hoekman*1, T. Hummel2, T. de Meij3, B. Koot1, M. Tabbers1, A. Vlieger4, A. Kindermann1, M. Benninga1

1Academic Medical Centre (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 2Medisch Spectrum Twente, Department of Paediatrics, Enschede, Netherlands, 3VU University Medical Centre, Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 4St. Antonius Hospital, Department of Paediatrics, Nieuwegein, Netherlands

P344: Non-adherence to medical therapy is associated with hospitalisations and the development of active disease in inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

M. Severs*1, H. H. Fidder1, M.-J. Mangen2, M. E. van der Valk1, M. van der Have1, A. A. van Bodegraven3, 4, C. H. M. Clemens5, G. Dijkstra6, J. M. Jansen7, D. J. de Jong8, N. Mahmmod9, P. C. van de Meeberg10, A. E. van der Meulen- de Jong11, M. Pierik12, C. Y. Ponsioen13, M. J. L. Romberg- Camps3, P. D. Siersema1, J. R. Vermeijden14, J. van der Woude15, P. N. Zuithoff16, B. Oldenburg1

1University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands, 2University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands, 3ORBIS medical Centre, Gastroenterology and Hepatology, Sittard, Netherlands, 4VU medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 5Diaconessenhuis, Gastroenterology and Hepatology, Leiden, Netherlands, 6University Medical Centre Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 7Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 8University Medical Centre St. Radboud, Gastroenterology and Hepatology, Nijmegen, Netherlands, 9Antonius Hospital, Gastroenterology and Hepatology, Nieuwegein, Netherlands, 10Slingeland Hospital, Gastroenterology and Hepatology, Doetinchem, Netherlands, 11Leiden University Medical Centre, Gastroenterology and Hepatology, Leiden, Netherlands, 12University Medical Centre Maastricht, Gastroenterology and Hepatology, Maastricht, Netherlands, 13Academic Medical Centre Amsterdam, Gastroenterology and Hepatology, Amsterdam, Netherlands, 14Meander Medical Centre, Gastroenterology and Hepatology, Amersfoort, Netherlands, 15Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands, 16University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands

P345: The Great Continental Divide: use of anti-TNF therapy in paediatric inflammatory bowel disease is significantly different in North America compared with other parts of the world.ECCO '16 Amsterdam
Year: 2016
Authors:

P. Church1, J. Hyams2, F. Ruemmele3, L. de Ridder4, D. Turner5, A. Griffiths*1, o.b.o. the International Paediatric IBD Network (PIBDNet)6

1Hospital for Sick Children, University of Toronto, Department of Gastroenterology, Hepatology and Nutrition, Toronto, Canada, 2Connecticut Children’s Medical Centre, Hartford, United States, 3Hospital Necker Enfants Malades, Department of Paediatric Gastroenterology, Paris, France, 4Children’s Hospital Erasmus MC Sophia, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 5Shaare Zedek Medical Centre, Department of Paediatric Gastroenterology, Jerusalem, Israel, 6International Paediatric IBD Network (PIBDNet), Paris, France

P346: Soluble transferrin receptor and its relation to anaemia in inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

R. Dudkowiak*, K. Neubauer, E. Poniewierka

Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

P347: Identification of a cut-off for persistent anti-infliximab antibodies as a predictor of response to infliximab monotherapyECCO '16 Amsterdam
Year: 2016
Authors:

L. Del Nero*1, G. Bodini2, E. Giannini2, J. Anjali3, V. Savarino1, E. Savarino4

1University of Genoa, Internal Medicine Department, Genoa, Italy, 2University of Genoa, Department of Gastroenterology and Internal Medicine, Genoa, Italy, 3Prometheus Laboratories, Department of Research and Development, San Diego, California, United States, 4University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Padua, Italy

P348: Novel model of care: the effect of a combined inflammatory bowel disease and antenatal clinicECCO '16 Amsterdam
Year: 2016
Authors:

C. Selinger*1, N. Carey1, G. Ulivi2, L. Walker2, F. Shaik1, T. Glanville2

1St James University Hospital, Gastroenterology, Leeds, United Kingdom, 2St James University Hospital, Obstetrics, Leeds, United Kingdom

P349: The effects of smoking on thiopurine metabolismECCO '16 Amsterdam
Year: 2016
Authors:

B. Warner*1, E. Johnston1, S. Fong1, P. Blaker1, M. Arenas-Hernandez2, A. Marinaki2, J. Sanderson1

1Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2Guy’s and St Thomas’ NHS Foundation Trust, Purine Laboratory, Viapath, London, United Kingdom

P350: The use of concomitant immunomodulators with adalimumab therapy in paediatric Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

K. Benkov*1, G. Russell2, C. Samson3, S. Steiner4, E.C. King5, J. Pratt5, S. Eichner6, R.B. Colletti7, ImproveCareNow Network8

1Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology, New York, New York, United States, 2Boston Children’s Hospital, Harvard School of Medicine, Boston, Massachusetts, United States, 3Washington University School of Medicine, Saint Louis, Missouri, United States, 4Riley Hospital for Children, Pediatric Gastroenterology, Hepatology and Nutrition, Indianapolis, Indiana, United States, 5Cincinnati Children’s Hospital Medical Centre, Division of Biostatistics and Epidemiology, Cincinnati, Ohio, United States, 6AbbVie, Chicago, Illinois, United States, 7University of Vermont Children’s Hospital, Burlington, Vermont, United States, 8ImproveCareNow, Burlington, Vermont, United States

P351: Faecal calprotectin correlates well with extent of active endoscopic inflammation in patients with ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

D. Chayut1, M. Kaplan2, Y. Chowers3, M. Waterman*3

1The Technion - Israel Institute of Technology, B. Rappaport Faculty of Medicine, Haifa, Israel, 2Rambam Health Care Campus, Department of Laboratory Medicine, Haifa, Israel, 3Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel

P352: Melanoma in a population-based Australian inflammatory bowel disease cohortECCO '16 Amsterdam
Year: 2016
Authors:

G. Hume*

University of Queensland, School of Medicine, Brisbane, Australia

P353: Endoscopy-based management within the first year after surgery decreases the risk of clinical and surgical postoperative recurrences in Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

A.-L. Boucher1, B. Pereira2, S. Decousus3, M. Goutte1, 4, F. Goutorbe1, A. Dubois5, J. Gagnière5, C. Borderon6, J. Joubert3, D. Pezet5, M. Dapoigny1, P. Dechelotte3, G. Bommelaer1, 4, A. Buisson*1, 4

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2DRCI, Biostatistics Unit, Clermont-Ferrand, France, 3University Hospital Estaing, Pathology Department, Clermont-Ferrand, France, 4UMR 1071 Inserm/Université d’Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, 5CHU Estaing, Department of Digestive surgery, Clermont-Ferrand, France, 6University Hospital Estaing, Paediatrics Department, Clermont-Ferrand, France

P354: A prospective randomised study: 2 mg/kg/d of azathioprine is an appropriate dosage for Chinese patients with Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

Y. Zhang*, J. Xia, Q. Cao

Sir Runrun Shaw Hospital, Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China

P355: Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

D. Seah*1, 2, M. Choy1, 2, 3, A. Gorelik4, F. Macrae5, M. Sparrow6, W.R. Connell3, G. Moore7, D. Van Langenberg8, P. De Cruz1, 2

1Austin Health, Department of Gastroenterology, Melbourne, Australia, 2University of Melbourne, Department of Medicine, Melbourne, Australia, 3St Vincent’s Hospital, Department of Gastroenterology, Melbourne, Australia, 4Royal Melbourne Hospital, Melbourne EpiCentre, Melbourne, Australia, 5Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia, 6The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia, 7Monash Health, Department of Gastroenterology, Melbourne, Australia, 8Eastern Health, Department of Gastroenterology, Melbourne, Australia

P356: Efficacy and safety of certolizumab pegol in Crohn’s disease patients with loss of response or intolerance to previous anti-TNFECCO '16 Amsterdam
Year: 2016
Authors:

I. Ferrer Bradley*1, I. Marín2, N. Maroto1, M. Mora1, E. Hinojosa1, B. López2, L. Menchén2, J. Hinojosa1

1Hospital de Manises, Gastroenterology, Valencia, Spain, 2Hospital Gregorio Marañón, Gastroenterology, Madrid, Spain

P357: Do you think that complementary and alternative medicine use is frequent amongst inflammatory bowel disease patients: Forget it!—results from a comparative studyECCO '16 Amsterdam
Year: 2016
Authors:

M. Rutka*1, T. Ferenci2, F. Nagy1, Z. Szepes1, K. Farkas1, A. Bálint1, R. Bor1, A. Milassin1, Z. Lénárt1, T. Molnar1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2John von Neumann Faculty of Informatics of Óbuda University, Budapest, Hungary